Literature DB >> 26077660

Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats.

Magdalena Jastrzębska-Więsek1, Agata Siwek, Anna Partyka, Bernadeta Szewczyk, Magdalena Sowa-Kućma, Anna Wasik, Marcin Kołaczkowski, Anna Wesołowska.   

Abstract

The study was designed to examine the potency of EMD 386088, a 5-HT6 receptor partial agonist, to exert antidepressant-like properties in animal models following acute and chronic intraperitoneal administration to rats. The modified rat forced swim test (FST) was utilized to examine a potential antidepressant effect of EMD 386088 after acute treatment (30 min before the test) and three times in a 24-h administration scheme (24 h, 5 h, and 30 min prior to the FST). The olfactory bulbectomy (OB) model was used to assess its antidepressant-like properties after chronic treatment (the drug was administered once daily for 14 days). EMD 386088 showed an antidepressant-like effect in all conducted tests. Its activity in FST after its acute administration (5 mg/kg) was blocked by the selective 5-HT6 receptor antagonist SB 271046. The obtained results seem to be specific, as there was no observed locomotor stimulation by the drug given at a lower/antidepressant dose. In the three times in the 24-h treatment scheme, EMD 386088 (2.5 mg/kg) exerted antidepressant properties in FST as well as increased locomotor activity in the open field test. Chronic administration of EMD 386088 (2.5 mg/kg) significantly improved the learning deficit in OB rats without affecting performance in Sham-operated (SH) animals in the passive avoidance test, and reduced OB-related rats' locomotor hyperactivity, but did not change the number of rearing + peeping episodes. The obtained findings suggest that EMD 386088 produces antidepressant-like activity after systemic acute and chronic administration which may result from direct stimulation of 5-HT6 receptors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26077660     DOI: 10.1007/s00210-015-1141-2

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  48 in total

1.  A microdialysis study of ST1936, a novel 5-HT6 receptor agonist.

Authors:  V Valentini; R Frau; F Bordi; F Borsini; G Di Chiara
Journal:  Neuropharmacology       Date:  2010-12-23       Impact factor: 5.250

Review 2.  An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function.

Authors:  Kevin C F Fone
Journal:  Neuropharmacology       Date:  2008-07-04       Impact factor: 5.250

3.  Effects of the 5-HT(6) receptor agonist ST 1936 on depression- and anhedonia-like experimental models.

Authors:  Simona Scheggi; Giovanna Marchese; Franco Borsini; Fabio Bordi; Maria Graziella De Montis
Journal:  Behav Brain Res       Date:  2011-05-27       Impact factor: 3.332

4.  The effect of (+/-)mianserin and its enantiomers on the behavioural hyperactivity of the olfactory-bulbectomized rat.

Authors:  S M Jancsár; B E Leonard
Journal:  Neuropharmacology       Date:  1984-09       Impact factor: 5.250

5.  Olfactory projection systems, drugs and behaviour: a review.

Authors:  K D Cairncross; B Cox; C Forster; A F Wren
Journal:  Psychoneuroendocrinology       Date:  1979-07       Impact factor: 4.905

6.  Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants.

Authors:  Eiji Shimizu; Kenji Hashimoto; Naoe Okamura; Kaori Koike; Naoya Komatsu; Chikara Kumakiri; Michiko Nakazato; Hiroyuki Watanabe; Naoyuki Shinoda; Sin-ichi Okada; Masaomi Iyo
Journal:  Biol Psychiatry       Date:  2003-07-01       Impact factor: 13.382

7.  A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation.

Authors:  M Ruat; E Traiffort; J M Arrang; J Tardivel-Lacombe; J Diaz; R Leurs; J C Schwartz
Journal:  Biochem Biophys Res Commun       Date:  1993-05-28       Impact factor: 3.575

8.  The effects of fluoxetine and zimeldine on the behavior of olfactory bulbectomized rats.

Authors:  D Joly; D J Sanger
Journal:  Pharmacol Biochem Behav       Date:  1986-02       Impact factor: 3.533

9.  The effect of tianeptine and sertraline in three animal models of depression.

Authors:  J P Kelly; B E Leonard
Journal:  Neuropharmacology       Date:  1994-08       Impact factor: 5.250

10.  Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation.

Authors:  Per Svenningsson; Eleni T Tzavara; Hongshi Qi; Robert Carruthers; Jeffrey M Witkin; George G Nomikos; Paul Greengard
Journal:  J Neurosci       Date:  2007-04-11       Impact factor: 6.167

View more
  5 in total

1.  Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner.

Authors:  Kristina Holubova; Lenka Kleteckova; Martina Skurlova; Jan Ricny; Ales Stuchlik; Karel Vales
Journal:  Psychopharmacology (Berl)       Date:  2016-03-23       Impact factor: 4.530

2.  Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats.

Authors:  Magdalena Jastrzębska-Więsek; Agata Siwek; Anna Partyka; Lucyna Antkiewicz-Michaluk; Jerzy Michaluk; Irena Romańska; Marcin Kołaczkowski; Anna Wesołowska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-23       Impact factor: 3.000

3.  Metabolic and Cardiovascular Benefits and Risks of EMD386088-A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor.

Authors:  Magdalena Kotańska; Joanna Śniecikowska; Magdalena Jastrzębska-Więsek; Marcin Kołaczkowski; Karolina Pytka
Journal:  Front Neurosci       Date:  2017-02-08       Impact factor: 4.677

4.  Constitutive Activity of Serotonin Receptor 6 Regulates Human Cerebral Organoids Formation and Depression-like Behaviors.

Authors:  Qinying Wang; Xiaoxu Dong; Tingting Hu; Chao Qu; Jing Lu; Yue Zhou; Jinsong Li; Gang Pei
Journal:  Stem Cell Reports       Date:  2020-12-23       Impact factor: 7.765

5.  Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats.

Authors:  Magdalena Jastrzębska-Więsek; Agata Siwek; Anna Partyka; Marcin Kołaczkowski; Maria Walczak; Magdalena Smolik; Gniewomir Latacz; Katarzyna Kieć-Kononowicz; Anna Wesołowska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-10-27       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.